PMID- 37820473
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231021
IS  - 1936-5233 (Print)
IS  - 1936-5233 (Electronic)
IS  - 1936-5233 (Linking)
VI  - 38
DP  - 2023 Dec
TI  - Charting new frontiers: Co-inhibitory immune checkpoint proteins in therapeutics, 
      biomarkers, and drug delivery systems in cancer care.
PG  - 101794
LID - S1936-5233(23)00180-8 [pii]
LID - 10.1016/j.tranon.2023.101794 [doi]
LID - 101794
AB  - Cancer remains a major health concern globally. Immune checkpoint inhibitors 
      (ICIs) target co-inhibitory immune checkpoint molecules and have received 
      approval for treating malignancies like melanoma and non-small cell lung cancer. 
      While CTLA-4 and PD-1/PD-L1 are extensively researched, additional targets such 
      as LAG-3, TIGIT, TIM-3, and VISTA have also demonstrated effective in cancer 
      therapy. Combination treatments, which pair ICIs with interventions such as 
      radiation or chemotherapy, amplify therapeutic outcomes. However, ICIs can lead 
      to diverse side effects, and their varies across patients and cancers. Hence, 
      identifying predictive biomarkers to guide therapy is essential. Notably, 
      expression levels of molecules like PD-1, CTLA-4, and LAG-3 have been linked to 
      tumor progression and ICI therapy responsiveness. Recent advancements in drug 
      delivery systems (DDSs) further enhance ICI therapy efficacy. This review 
      explores predominant DDSs for ICI delivery, such as hydrogel, microparticle, and 
      nanoparticle, which offer improved therapeutic effects and reduced toxicity. In 
      summary, we discuss the future of immune therapy focusing on co-inhibitory 
      checkpoint molecules, pinpoint challenges, and suggest avenues for developing 
      efficient, safer DDSs for ICI transport.
CI  - Copyright (c) 2023. Published by Elsevier Inc.
FAU - Xiao, Yao
AU  - Xiao Y
AD  - State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key 
      Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of 
      Stomatology, School & Hospital of Stomatology, Wuhan University, Wuhan, 430079, 
      China.
FAU - Li, Zi-Zhan
AU  - Li ZZ
AD  - State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key 
      Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of 
      Stomatology, School & Hospital of Stomatology, Wuhan University, Wuhan, 430079, 
      China.
FAU - Zhong, Nian-Nian
AU  - Zhong NN
AD  - State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key 
      Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of 
      Stomatology, School & Hospital of Stomatology, Wuhan University, Wuhan, 430079, 
      China.
FAU - Cao, Lei-Ming
AU  - Cao LM
AD  - State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key 
      Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of 
      Stomatology, School & Hospital of Stomatology, Wuhan University, Wuhan, 430079, 
      China.
FAU - Liu, Bing
AU  - Liu B
AD  - State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key 
      Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of 
      Stomatology, School & Hospital of Stomatology, Wuhan University, Wuhan, 430079, 
      China; Department of Oral & Maxillofacial - Head Neck Oncology, School & Hospital 
      of Stomatology, Wuhan University, Wuhan, 430079, China.
FAU - Bu, Lin-Lin
AU  - Bu LL
AD  - State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key 
      Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of 
      Stomatology, School & Hospital of Stomatology, Wuhan University, Wuhan, 430079, 
      China; Department of Oral & Maxillofacial - Head Neck Oncology, School & Hospital 
      of Stomatology, Wuhan University, Wuhan, 430079, China. Electronic address: 
      lin-lin.bu@whu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20231009
PL  - United States
TA  - Transl Oncol
JT  - Translational oncology
JID - 101472619
PMC - PMC10582482
OTO - NOTNLM
OT  - Biomarker
OT  - Co-inhibitory immune checkpoint
OT  - Drug delivery system
OT  - Immune checkpoint inhibitor
OT  - Immunotherapy
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/10/12 00:43
MHDA- 2023/10/12 00:44
PMCR- 2023/10/09
CRDT- 2023/10/11 18:05
PHST- 2023/06/23 00:00 [received]
PHST- 2023/09/17 00:00 [revised]
PHST- 2023/09/29 00:00 [accepted]
PHST- 2023/10/12 00:44 [medline]
PHST- 2023/10/12 00:43 [pubmed]
PHST- 2023/10/11 18:05 [entrez]
PHST- 2023/10/09 00:00 [pmc-release]
AID - S1936-5233(23)00180-8 [pii]
AID - 101794 [pii]
AID - 10.1016/j.tranon.2023.101794 [doi]
PST - ppublish
SO  - Transl Oncol. 2023 Dec;38:101794. doi: 10.1016/j.tranon.2023.101794. Epub 2023 
      Oct 9.